Bower C M, Waner M, Flock S, Schaeffer R
Department of Otolaryngology-Head and Neck Surgery, Arkansas Children's Hospital, Little Rock 72202, USA.
Ann Otol Rhinol Laryngol. 1998 Dec;107(12):1001-5. doi: 10.1177/000348949810701201.
To evaluate the feasibility and safety of the flash pump dye (FPD) laser for the treatment of laryngeal papillomas, we performed a prospective nonrandomized trial comparing FPD and carbon dioxide (CO2) laser treatment of laryngeal papillomas in a tertiary care children's hospital. Nine patients from 2 to 20 years of age with severe recurrent laryngeal papillomas were enrolled in the study. All patients underwent CO2 laser debulking of papillomas on the left hemilarynx, with 8 W continuous or pulsed energy. The right hemilarynx was treated with the FPD laser with 12 to 77 pulses at 8 to 12 J, through a custom-designed 90 degrees firing fiber. An end point of blanching and purpura of the papillomas was used. The main outcome measures were the safety and ease of operation with the FPD laser, and decreased papilloma size based on visual inspection at 2 weeks postoperative and at the next laser procedure. Seven patients were irradiated I time with an FPD laser, and 2 patients 2 times. No intraoperative complications were noted. One patient developed early postoperative stridor. No patients described more discomfort, and 5 patients described their voice as being the same as or better than it was after prior CO2 laser procedures. Five patients had a 90% or more decrease in size of papillomas on the FPD-irradiated side 2 weeks postoperatively. Three patients had approximately a 50% reduction. A treatment effect was noted in all patients, and was similar to the results noted on the CO2 laser-treated side. Early results with FPD laser treatment of laryngeal papillomas suggest the protocol is relatively safe and feasible. Long-term results are pending. Because the FPD laser coagulates rather than vaporizing tissue, potential advantages may include decreased scarring relative to CO2 laser treatment, and improved patient and operator safety.
为评估闪泵染料(FPD)激光治疗喉乳头状瘤的可行性和安全性,我们在一家三级儿童专科医院进行了一项前瞻性非随机试验,比较FPD激光和二氧化碳(CO2)激光治疗喉乳头状瘤的效果。9名年龄在2至20岁之间、患有严重复发性喉乳头状瘤的患者被纳入研究。所有患者均接受CO2激光对左半喉乳头状瘤进行减容治疗,能量为8W连续或脉冲能量。右半喉则通过定制设计的90度发射光纤,使用FPD激光以8至12J的能量进行12至77次脉冲治疗。以乳头状瘤变白和出现紫癜作为终点。主要观察指标为FPD激光操作的安全性和简便性,以及术后2周和下次激光治疗时通过肉眼观察乳头状瘤大小的减小情况。7名患者接受了1次FPD激光照射,2名患者接受了2次照射。术中未发现并发症。1名患者术后早期出现喘鸣。没有患者表示更不适,5名患者称其声音与之前CO2激光治疗后相同或更好。5名患者在术后2周时,FPD激光照射侧的乳头状瘤大小减小了90%或更多。3名患者的乳头状瘤大小约减小了50%。所有患者均观察到治疗效果,且与CO2激光治疗侧的结果相似。FPD激光治疗喉乳头状瘤的早期结果表明该方案相对安全可行。长期结果有待观察。由于FPD激光使组织凝固而非汽化,潜在优势可能包括相对于CO2激光治疗减少瘢痕形成,以及提高患者和操作者的安全性。